Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift

Recent Advances in the Treatment of Melanoma

Frontiers Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone

Is earlier better for melanoma checkpoint blockade?

Neoadjuvant immunotherapy: Results in melanoma show promise and pave the way for other solid tumors

IJMS, Free Full-Text

SWOG S1801: Pathologic Response With Neoadjuvant vs Adjuvant Pembrolizumab in Resectable Stage IIIb–IV Melanoma

Neoadjuvant pembrolizumab administered before surgery improves outcomes of melanoma patients: phase 2 clinical trial findings

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial